Search results for "malattie"

showing 10 items of 1963 documents

Sleep Apnea, Sleepiness, and Driving Risk

2019

Obstructive sleep apnea is associated with excessive daytime sleepiness in about 50% of cases, and with increased risk of driving accidents. Treatment with continuous positive airway pressure effectively decreases such risk, but compliance with continuous positive airway pressure treatment is often suboptimal. According to the European Union Directive on driving risk, retention of a driving license in patients with obstructive sleep apnea requires assessment of sleepiness and adherence to continuous positive airway pressure treatment, but there remains uncertainty on the optimal methods to assess sleepiness on a large scale.

Automobile Drivingmedicine.medical_specialtySleepinessmedicine.medical_treatmentDriving riskExcessive daytime sleepinessSubjective sleepineSettore MED/10 - Malattie Dell'Apparato RespiratorioObjective sleepine03 medical and health sciencesSleep Apnea SyndromesSleep Apnea Syndrome0302 clinical medicineRisk FactorsCPAPEpidemiologymedicineHumansmedia_common.cataloged_instanceContinuous positive airway pressureWakefulnessEuropean unionobstructive sleep apneapathophysiologymedia_commonContinuous Positive Airway Pressurebusiness.industryRisk FactorWakefulneSleep apneaGeneral Medicinemedicine.diseasesubjective sleepinessrespiratory tract diseasesObstructive sleep apneaPsychiatry and Mental healthClinical PsychologyNeuropsychology and Physiological Psychology030228 respiratory systemEmergency medicineobjective sleepinessPatient ComplianceepidemiologyNeurology (clinical)medicine.symptombusinessOptimal methods030217 neurology & neurosurgeryHumanSleep Medicine Clinics
researchProduct

Is diet partly responsible for differences in COVID-19 death rates between and within countries?

2020

Abstract Reported COVID-19 deaths in Germany are relatively low as compared to many European countries. Among the several explanations proposed, an early and large testing of the population was put forward. Most current debates on COVID-19 focus on the differences among countries, but little attention has been given to regional differences and diet. The low-death rate European countries (e.g. Austria, Baltic States, Czech Republic, Finland, Norway, Poland, Slovakia) have used different quarantine and/or confinement times and methods and none have performed as many early tests as Germany. Among other factors that may be significant are the dietary habits. It seems that some foods largely use…

BLOOD-PRESSUREReviewAngiotensin-converting enzyme; Antioxidant; Coronavirus; Diet; Foodlaw.inventionDietary interventions0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases10183 Swiss Institute of Allergy and Asthma ResearchlawMedicine and Health SciencesImmunology and AllergyMedicine030212 general & internal medicine[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseaseseducation.field_of_studyMortality rate3. Good health[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases2723 Immunology and AllergyAntioxidantAngiotensin-converting enzymeAngiotensin-converting enzyme Antioxidant Coronavirus Diet FoodPulmonary and Respiratory Medicine2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)CoronaviruImmunologyPopulation610 Medicine & healthCOVID-19 ; Food ; Angiotensin-converting enzyme ; Diet ; Antioxidant ; CoronavirusSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesEnvironmental healthCOVID-19 ; population ; angiotensin-converting enzymeQuarantineeducation2403 ImmunologyANTIHYPERTENSIVE PEPTIDESbusiness.industryRC581-607GENEPOLYMORPHISMDietCoronavirus[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition030228 respiratory system2740 Pulmonary and Respiratory MedicineFoodImmunologic diseases. Allergybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionRegional differencesCoronavirus Infections
researchProduct

GOLD Staging System is Appropriate to Predict Mortality in Older People With Chronic Obstructive Pulmonary Disease

2018

Abstract Introduction In the new GOLD classification the reduction of FEV1, expressed as percentage of predicted value (FEV1PP), is considered an important prognostic factor. However, the use of FEV1PP may introduce bias, especially if based on equations derived from populations different from the one under study. We evaluated how well the GOLD classification stratifies the mortality risk when FEV1PP is based on an equation developed in the same population that gave rise to cases, externally developed equations, or as FEV1 divided by cubed height (FEV1/Ht3). Methods We studied 882 participants aged ≥65 years. Bronchial obstruction was defined using a fixed cut-off of 0.7 for FEV1/FVC. Predi…

BODE indexPulmonary and Respiratory Medicinemedicine.medical_specialtyPopulationPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesFEV1/FVC ratioFEV10302 clinical medicineElderlyInternal medicinemedicine030212 general & internal medicineGOLDeducationStaging systemCOPDeducation.field_of_studybusiness.industryChronic obstructive pulmonary diseaseHazard ratioGeneral Medicinerespiratory systemmedicine.diseaserespiratory tract diseases030228 respiratory systemQuartilebusiness
researchProduct

Occupational therapy, degree of disability and quality of life in COPD inpatients undergoing pulmonary rehabilitation programs

2010

BPCOSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

Broncopneumopatia cronica ostruttiva

2011

BPCOSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

Collagen I, III and IV content in airways and lung parenchyma of COPD patients

2010

BPCOSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

Effects of pulmonary rehabilitation on systemic and pulmonary inflammation in COPD patients

2010

BPCOSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

Protocol of BRONJ prevention: successful use of antiseptics during oral surgical procedures

2012

Aim: The overall prevention and treatment of Bisphosphonates related osteonecrosis of the jaws (BRONJ) have been the goals of our project structured (labelled PROMaB) within the hospital AOUP “P. Giaccone” (Italy) in order to make better quality life of patients in therapy with amminobisphosphonates (NBP). Material and Methods: Among all procedures, in case of preprogrammed oral surgical procedure, oral antimicrobial rinses (i.e. chlorexidine 0,2% mouthwash and 0,5% gel, three times/day) plus oral systemic antibiotic therapy –e.g. amoxicilin/clavulanate- have been used to reduce the risk of BRONJ in secondary prevention (1 day before and 6 days after). Three hundred and twenty-one patients …

BRONJ prevention antiseptics oral surgerySettore MED/28 - Malattie Odontostomatologiche
researchProduct

Hypertension treatment in patients with sleep apnea from the European Sleep Apnea Database (ESADA) cohort - towards precision medicine.

2022

We recruited 5,970 patients with hypertension with obstructive sleep apnea (OSA) on current antihypertensive treatment from the European Sleep Apnea Database (ESADA) cohort. The group was subdivided into those receiving monotherapy (n = 3,594) and those receiving dual combined therapy (n = 2,376). We studied how major OSA confounders like age, gender, and body mass index as well as the degree of sleep apnea modified office systolic and diastolic blood pressure. Beta-blockers alone or in combination with a diuretic were compared with other antihypertensive drug classes. Monotherapy with beta-blocker was associated with lower systolic blood pressure, particularly in non-obese middle-aged male…

Behavioral NeurosciencehypertensionCognitive Neurosciencediureticbeta-blockerobstructive sleep apnea.General MedicineSettore MED/10 - Malattie Dell'Apparato Respiratorioantihypertensive treatmentJournal of sleep researchREFERENCES
researchProduct

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.

2018

Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revis…

BendamustineAdultMalemedicine.medical_specialtyPhases of clinical researchNeutropeniaGastroenterologyDisease-Free SurvivalDrug Administration ScheduleSettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicineInternal medicinefirst-line therapyAntineoplastic Combined Chemotherapy ProtocolsMedicineBendamustine HydrochlorideHumansSplenic marginal zone lymphomabendamustineAgedbusiness.industrySplenic NeoplasmsHematologyLymphoma B-Cell Marginal ZoneMiddle Agedmedicine.diseaseLymphomaimmunochemotherapyRegimenTreatment Outcome030220 oncology & carcinogenesisbendamustine; first-line therapy; immunochemotherapy; rituximab; Splenic Marginal Zone Lymphoma; HematologySplenectomyRituximabFemaleSplenic Marginal Zone LymphomaNeoplasm Recurrence LocalbusinessRituximabFebrile neutropenia030215 immunologymedicine.drugBritish journal of haematology
researchProduct